Lantern Pharma Inc.
Lantern Pharma Inc. (LTRN): 5 pipeline candidates · ~5 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
5.1 months
D/E 1.10 · 0% dilution
Lead: Phase 2
5 candidates
N/A
2 buys · 0 sells (180d)
A transparent, data-derived signal for Lantern Pharma Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$47.6M
Cash
$4.9M
Quarterly Burn
$3.8M
Runway
5.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| cryptophycin-adc | Preclinical |
| lp-100 | Phase 2 |
| lp-184 | Phase 1/Phase 2 |
| lp-284 | Phase 1 |
| lp-300 | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
29
Total value held
$2.8M
| Holder | Shares | Value |
|---|---|---|
| bios capital management, lp | 864,435 | $1.2M |
| vanguard capital management llc | 664,158 | $910K |
| renaissance technologies llc | 116,000 | $159K |
| geode capital management, llc | 111,646 | $153K |
| vanguard fiduciary trust co | 49,607 | $68K |
| blackrock, inc. | 45,267 | $62K |
| dimensional fund advisors lp | 38,060 | $52K |
| horizon kinetics asset management llc | 26,373 | $36K |
| davenport & co llc | 23,814 | $33K |
| state street corp | 23,652 | $32K |
Showing top 10 of 29 institutional holders of Lantern Pharma Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Lantern Pharma Inc.'s pipeline?
Lantern Pharma Inc. (LTRN) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Lantern Pharma Inc.'s lead drug candidate?
Lantern Pharma Inc.'s most advanced tracked candidate is cryptophycin-adc (Preclinical) for Solid tumors (breast, bladder, colorectal, gastric, pancreatic and ovarian).
What is Lantern Pharma Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Lantern Pharma Inc. has approximately 5.1 months of cash runway.
What is Lantern Pharma Inc.'s market capitalization?
Lantern Pharma Inc.'s market capitalization is approximately $47.6M.
Who is the CEO of Lantern Pharma Inc.?
Mr. Panna Sharma is the chief executive officer of Lantern Pharma Inc. (LTRN).
Get the full picture on Lantern Pharma Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.